BioSig Technologies Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

BioSig Technologies wird ein Gewinn- und Umsatzwachstum von 15.6% bzw. 225.9% pro Jahr prognostiziert, während der Gewinn pro Aktie um 36.8% pro Jahr wachsen soll.

Wichtige Informationen

15.6%

Wachstumsrate der Gewinne

36.8%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	17.1%
Wachstumsrate der Einnahmen	225.9%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	12 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Shareholders May Be More Conservative With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation For Now

Dec 12

Shareholders May Not Be So Generous With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation And Here's Why

Dec 14

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:BSGM - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	1	-12	N/A	-8	1
12/31/2024	N/A	-14	N/A	-7	1
9/30/2024	0	-15	-7	-7	N/A
6/30/2024	0	-18	-10	-10	N/A
3/31/2024	0	-25	-13	-13	N/A
12/31/2023	0	-29	-17	-17	N/A
9/30/2023	0	-30	-19	-18	N/A
6/30/2023	0	-32	-20	-20	N/A
3/31/2023	0	-27	-22	-21	N/A
12/31/2022	0	-27	-22	-22	N/A
9/30/2022	0	-29	-24	-23	N/A
6/30/2022	0	-30	-26	-25	N/A
3/31/2022	0	-32	-26	-25	N/A
12/31/2021	0	-32	-27	-26	N/A
9/30/2021	0	-34	-27	-27	N/A
6/30/2021	0	-38	-27	-26	N/A
3/31/2021	0	-49	-28	-28	N/A
12/31/2020	N/A	-52	-27	-27	N/A
9/30/2020	N/A	-57	-25	-24	N/A
6/30/2020	N/A	-51	-22	-22	N/A
3/31/2020	N/A	-40	-18	-18	N/A
12/31/2019	N/A	-34	-16	-15	N/A
9/30/2019	N/A	-25	-15	-15	N/A
6/30/2019	N/A	-23	-13	-13	N/A
3/31/2019	N/A	-21	-12	-11	N/A
12/31/2018	N/A	-18	-11	-10	N/A
9/30/2018	N/A	-17	-10	-10	N/A
6/30/2018	N/A	-15	N/A	-9	N/A
3/31/2018	N/A	-12	N/A	-8	N/A
12/31/2017	N/A	-13	N/A	-7	N/A
9/30/2017	N/A	-10	N/A	-6	N/A
6/30/2017	N/A	-9	N/A	-6	N/A
3/31/2017	N/A	-12	N/A	-6	N/A
12/31/2016	N/A	-12	N/A	-5	N/A
9/30/2016	N/A	-12	N/A	-5	N/A
6/30/2016	N/A	-11	N/A	-5	N/A
3/31/2016	N/A	-9	N/A	-4	N/A
12/31/2015	N/A	-10	N/A	-5	N/A
9/30/2015	N/A	-10	N/A	-4	N/A
6/30/2015	N/A	-15	N/A	-4	N/A
3/31/2015	N/A	-11	N/A	-3	N/A
12/31/2014	N/A	-9	N/A	-2	N/A
9/30/2014	N/A	-8	N/A	-2	N/A
6/30/2014	N/A	-6	N/A	-2	N/A
3/31/2014	N/A	-8	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BSGM wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: BSGM wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: BSGM wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: BSGMDie Einnahmen des Unternehmens (225.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: BSGMDie Einnahmen des Unternehmens (225.9% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von BSGM in 3 Jahren voraussichtlich hoch sein wird

BioSig Technologies Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 67%, EPS upgraded

Price target increased by 27% to US$5.63

Consensus revenue estimates decrease by 24%

Price target increased by 8.0% to US$4.50

Consensus EPS estimates fall by 24%

Consensus revenue estimates decrease by 65%, EPS upgraded

Recent updates

BioSig Technologies, Inc., Annual General Meeting, Dec 31, 2024

BioSig Technologies' Common Stock Deleted from OTC Equity

Nasdaq Hearings Panel Determines to Delist BioSig Technologies' Common Stock

BioSig Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $3.000005 million.

BioSig Technologies, Inc. announced delayed 10-Q filing

BioSig Technologies Regains Compliance with the Minimum Bid Price Requirements in Listing Rule 5550(a)(2)

BioSig Technologies, Inc. Appoints Anthony Amato as Chief Executive Officer

BioSig Technologies, Inc. announced delayed annual 10-K filing

BioSig Technologies Receives Letter from Nasdaq Regarding No Longer Meets the Requirement of Rule 5550(b)(2)

BioSig Technologies Receives a Letter from the Listing Qualifications Department of Nasdaq Stating That the Company Has Not Regained Compliance with the Rule

Biosig Technologies, Inc. Announces Resignation of Kenneth L. Londoner as Chief Executive Officer

BioSig Announces Reduction of its Workforce

Biosig Technologies, Inc. Commences Workforce Reduction Consisted of the Departure of Sixteen Employees

BioSig Technologies, Inc. announced that it expects to receive $1.04 million in funding

BioSig Technologies Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Market Value of Listed Securities

Consensus revenue estimates decrease by 67%, EPS upgraded

Shareholders May Be More Conservative With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation For Now

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

BioSig Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $2.5 million.

BioSig Technologies, Inc. has filed a Follow-on Equity Offering.

BioSig Technologies, Inc. has filed a Follow-on Equity Offering.

Biosig Technologies, Inc. Appoints Fred Hrkac as Executive Vice President

BioSig Technologies, Inc., Annual General Meeting, Dec 18, 2023

BioSig Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $0.13464 million.

BioSig Technologies, Inc. announced that it has received $0.597497 million in funding

Price target increased by 27% to US$5.63

Consensus revenue estimates decrease by 24%

BioSig Technologies, Inc. announced that it has received $0.549999 million in funding

BioSig Technologies, Inc. Achieves Infrastructure and Technology Progress in Development of Generative AI Platform for Hospitals

Biosig Technologies, Inc. Introduces New Subscription Model for Pure Ep™ Platform, Offering Quicker Access to Latest Features, Customers

Biosig Technologies, Inc.'s Pure Ep Platform Debuts New Automated Features in First Patient Cases

Second quarter 2023 earnings released: US$0.16 loss per share (vs US$0.15 loss in 2Q 2022)

New minor risk - Share price stability

BioSig Technologies, Inc. Advances Collaboration on Machine Learning and Artificial Intelligence Solutions for Healthcare

Price target increased by 8.0% to US$4.50

Consensus EPS estimates fall by 24%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 65%, EPS upgraded

BioSig Technologies, Inc. Announces Chief Financial Officer Changes

BioSig Technologies, Inc. announced that it has received $1.299999 million in funding

BioSig Technologies, Inc. announced that it expects to receive $0.159998 million in funding

BioSig Technologies, Inc. announced that it expects to receive $1.299999 million in funding

BioSig's PURE EP(TM) System Demonstrates Potential Time and Cost Savings At the 15th APHRS Scientific Session in Singapore

Shareholders May Not Be So Generous With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation And Here's Why

BioSig Technologies Receives a Letter from the Nasdaq Stock Market

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$4.17

BioSig Technologies, Inc., Annual General Meeting, Dec 20, 2022

BioSig Technologies Receives Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price

BioSig in acquisition pact with San Antonio Hospital for cardiac signal system

BioSig Technologies, Inc. Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module

BioSig: No Changes To Hold Thesis Following Q2 Earnings

Consensus forecasts updated

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

BioSig Technologies Receives Non-Compliance Letter from Nasdaq

Consensus revenue estimates fall by 55%

BioSig signs purchase deal with Kansas City's Overland Park Regional hospital

BioSig: PURE EP Economics Trade Exhausted

BioSig Technologies, Inc.’s PURE EP™ System to be Featured During EPLive 2022

Consensus revenue estimates fall by 18%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$8.50

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken